Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Contract win

6 Jun 2018 07:00

RNS Number : 4052Q
Instem plc
06 June 2018
 

6 June 2018

Instem plc

("Instem")

 

Contract win

 

Leading Fortune 500 Company adopts Instem's Samarind RMS solution for its worldwide medical products regulatory tracking system

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that a leading Fortune 500 medical products and pharmaceuticals company has adopted Instem's Samarind RMS Software-as-a-Service ("SaaS") solution. The contract is worth approximately US$750,000 incorporating both perpetual license and SaaS revenue streams with c. 80% of the contract value being recognised in 2018 and annual recurring revenue of US$169,000.

 

Samarind RMS provides medical device and pharmaceutical companies with a smarter way to manage their Product Information, facilitating initial marketing authorisation and supporting ongoing regulatory compliance. The product is optimised to enable these companies to register and track their regulated products worldwide by maintaining a single integrated database of all relevant information, which is then used to update regulators as products change over time. The comprehensive functionality provided by Samarind RMS enables customers to systematically define and execute complex regulatory activities across a globally dispersed workforce whilst providing a single place to find, analyse and act on a wealth of product and regulatory information.

 

Phil Reason, CEO of Instem plc, said: "This contract win with a global company, which ranks among the top 25 on the Fortune 500, continues the good momentum experienced with our regulatory information management solutions 2017 to date and particularly Instem's success in the medical device field. We are very pleased to be delivering this as a SaaS agreement."

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

 

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Richard Lindley

James White

 

 

 

Walbrook Financial PR

+44 (0) 20 7933 8780

Paul Cornelius

instem@walbrookpr.com

Helen Cresswell

Sam Allen

 

 

 

 

 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

 

To learn more about Instem solutions and its mission, please visit instem.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFKPDKABKDAAK
Date   Source Headline
8th Sep 20232:15 pmRNSForm 8.3 - Instem plc
8th Sep 20232:00 pmRNSForm 8 (OPD) - Instem plc
8th Sep 20231:58 pmPRNForm 8.3 - Instem Plc
8th Sep 20239:50 amRNSForm 8.5 (EPT/RI)
7th Sep 20233:03 pmRNSForm 8.3 - Instem plc
7th Sep 20233:00 pmBUSForm 8.3 - INS LN
7th Sep 20231:54 pmPRNForm 8.3 - Instem Plc
7th Sep 202311:07 amRNSForm 8.3 - Instem Plc
7th Sep 202310:12 amRNSForm 8.5 (EPT/RI)
5th Sep 20236:00 pmRNSReplacement: Form 8 (OPD) - Instem plc
5th Sep 20234:15 pmRNSForm 8 (OPD) - Instem plc
5th Sep 20231:38 pmPRNForm 8.3 - Instem Plc
5th Sep 202310:48 amRNSForm 8.5 (EPT/RI)
5th Sep 20239:55 amRNSForm 8.3 - Instem Plc
4th Sep 20234:50 pmRNSForm 8.3 - Instem plc
4th Sep 20239:58 amRNSForm 8.5 (EPT/RI)
1st Sep 20233:00 pmBUSForm 8.3 - INS LN
1st Sep 20232:15 pmGNWForm 8.3 - Instem PLC
1st Sep 20231:29 pmPRNForm 8.3 - Instem Plc
1st Sep 202312:05 pmRNSForm 8.5 (EPT/RI)
1st Sep 202311:25 amRNSForm 8.3 - Instem plc
1st Sep 20237:00 amBUSForm 8.3 - Instem plc
31st Aug 20234:45 pmPRNRe-issue: Form 8.3 - Instem Plc
31st Aug 20233:00 pmBUSForm 8.3 - INS LN
31st Aug 202312:02 pmRNSForm 8.3 - Instem plc
31st Aug 202312:00 pmRNSForm 8.5 (EPT/RI) - Instem plc
31st Aug 202311:44 amGNWForm 8.3 - [Instem plc - Opening Declaration - 30 08 2023] - (CGAML)
31st Aug 202311:15 amRNSForm 8.3 - Instem PLC
31st Aug 202310:29 amGNWForm 8.3 - Instem PLC
31st Aug 202310:07 amRNSForm 8.3 - Instem Plc
31st Aug 202310:02 amBUSForm 8.3 - INSTEM PLC
31st Aug 202310:01 amRNSForm 8.3 - Instem Plc
31st Aug 20239:55 amRNSForm 8.3 - Instem plc
31st Aug 20239:44 amRNSForm 8.5 (EPT/RI)
31st Aug 20239:24 amRNSHolding(s) in Company
30th Aug 202312:09 pmRNSForm 8.3 - Instem plc
30th Aug 202311:26 amRNSForm 8.3 - Instem plc
30th Aug 202310:22 amBUSForm 8.3 - INSTEM PLC
30th Aug 202310:10 amRNSForm 8.3 - Instem Plc
30th Aug 20237:00 amRNSRecommended Cash Offer
15th Aug 20237:00 amRNSTrading Update
3rd Aug 20237:30 amRNSHolding(s) in Company
31st Jul 20231:32 pmRNSHolding(s) in Company
28th Jul 202310:00 amRNSExercise of Options, Issue of Equity & TVR
27th Jul 20231:15 pmRNSHolding(s) in Company
28th Jun 20237:00 amRNSResult of AGM
2nd Jun 20238:51 amRNSNotice of AGM & Posting of Annual Report
2nd Jun 20238:38 amRNSExercise of Options, Issue of Equity & TVR
18th May 20239:14 amRNSHolding(s) in Company
15th May 20237:01 amRNSFinal Results & Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.